A stylized globe graphic, with the EU area emphasized
ISIDORe project home / Services / Support for Diagnostic & Therapeutic Development

SUPPORT FOR DIAGNOSTIC & THERAPEUTIC DEVELOPMENT

The best of chemical biology for advancing your prevention and intervention tools

SUPPORT FOR THE DEVELOPMENT OF DIAGNOSTICS

Provided to you by EU-OPENSCREEN Partners

Contacts
scientific-projects@eu-openscreen.eu

  • Characterization of in-vitro diagnostic devices and sensing platforms
    Electron microscopy (SEM-EDX, TEM-EDX); Surface analysis (XPS, TOF-SIMS); Raman Microscope; Array scanner
  • Lab-on-a-Chip molecular diagnostics, multiplexed pathogen detection, variant discrimination

SUPPORT FOR THE DEVELOPMENT OF SMALL MOLECULE THERAPEUTICS

Provided to you by: EU-OPENSCREEN, EU-OPENSCREEN Partners & ERINHA

Contacts
scientific-projects@eu-openscreen.eu

Small molecule libraries – provided ONLY in combination with high throughput screening (HTS) services offered below

  • Repurposing Library
    Preparation of assay-ready plates with drug repurposing libraries containing approved and clinical trial compounds
  • European Chemical Biology Library (ECBL)
    Preparation of assay-ready plates with 100.000 small molecules containing approx. 2464 bioactives
  • EU-OPENSCREEN Fragment Library
    Preparation of plates with approx. 1000 fragments including 88 minifrags
  • EU-OPENSCREEN Bioactives
    Preparation of plates with 2464 bioactives

Assay development, high throughput screening and hit profiling services for identification of active small molecule and host-targeting agents

  • Assay development
    Assay design and development in a broad range of readouts including phenotypic assays in BSL2-BSL3 facilities (bacterial growth inhibition and viral infection inhibition, cell-based HCS, host cell response), and BSL1 in-vitro target-based assays with specific bacterial, viral and human targets
  • Biochemical and enzymatic target-based high-throughput screening
    High-throughput screening using BSL1 in-vitro target-based assays with specific bacterial, viral and human targets. The assay needs to be HTS-compatible with demonstrated performance in 384-well format. The service includes assay transfer, HTS and hit validation
    Do not forget to request library if necessary.
  • Cell-based high-throughput screening
    Cell-based screen including phenotypic, and target-based that can be run in both, human and bacterial, cells in BSL2 facilities. The assay needs to be HTS-compatible with demonstrated performance in 384-well format. The service includes assay transfer, HTS and hit validation
    Do not forget to request library if necessary
  • Low- and medium-throughput screening in BSL3 facilities
    Cell-based screen including phenotypic, and target-based that can be run in human cells and pathogen infection models in BSL3 facilities. The service includes assay transfer, screening and hit validation
  • Fragment screening
    Includes assay development, screening and hit validation
  • Hit profiling
    ADMET, ROS-tox and others

ISIDORe Services in action

The blood-brain barrier is dysregulated in COVId-19 and serves as a CNS entry route for SARS-CoV-2 doi.org/10.1016/j.stemcr.2021.12.011

Characterization of ACE Inhibitors and AT1R Antagonists with Regard to Their Effect on ACE2 Expression and Infection with SARS-CoV-2 Using a Caco-2 Cell Model
doi.org/10.3390/life11080810

X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease
doi: 10.1126/science.abf7945

Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen
doi.org/10.1021/acsptsci.0c00216

A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection
doi.org/10.1038/s41597-021-00848-4

Medicinal chemistry support

  • Drug design & evaluation in silico
  • Hit-to-lead development following HTS of small molecules
  • Fragment-to-lead development fragment screening
  • Optimization of potency, selectivity and in vitro/in vivo ADMET properties of small molecule drug candidates
  • Design and synthesis of target degraders (PROTACs, RIBOTACs)

SUPPORT FOR THE DEVELOPMENT OF ANTIBODY THERAPEUTICS

Provided to you by: EU-OPENSCREEN, EU-OPENSCREEN Partners & ERINHA

Contacts
scientific-projects@eu-openscreen.eu

Library preparation

  • VHH library preparation
    Preparation of VHH libraries in phagmid vectors including pSEX81 and pMES4. Libraries from naive or immunized alpaca of very high efficiency.

Nanobody, antibody & antigen identification / engineering

  • Nanobody identification
    The service covers:
  • Protein overexpression in E. coli system (vector provided by applicant)
    • Protein purification and verification by mass spectrometry
    • Phage-display nanobody (VHH) library screen
    • Verification of positive clones by ELISA test
    • Nanobody sequence identification
    • Training
  • Antibody discovery and selection from B cells
    Identification of antibodies from plasma of convalescent patients by B-cell cloning
  • Antigen or antibody design and engineering
    Design and engineering of antibody with specific functions and suitable formats (IgG, Fab, single chain antibodies); engineering for increased stability, solubility, modulation of complement engagement, multi-specific constructs

Antibody and/or antigen production and characterization

  • Antigen and/or antibody production, purification and characterization
    Antibody and/or antigen production and purification, quality control of the samples, biophysical characterization (binding affinity, functionality, epitope mapping), in vitro neutralization assays
  • 3D structural models
    3D structural analysis of antibodies, antigens and antibody-antigen complexes with experimentally guided computational simulations
  • Physico-chemical measurements of quality attributes
    Structure, stability, aggregation (digital electrophoresis, DLS, CD, AUC, Multi Detector-AF4, SPR)
  • Assessment of endotoxin contamination
    LAL tests

Functional assays

  • Phenotypic antiviral screening – replication-competent system
    Evaluation of the selective antiviral activity of agents (antibodies) in virus-cell-based assays using replication-competent SARS-CoV-2
  • Phenotypic antiviral screening – pseudovirus system
    Evaluation of the selective antiviral activity of agents (antibodies) in virus-cell-based assays using SARS-CoV-2 pseudoviruses
  • Binding assays
    Binding tests on current and previous SARS2 variants using multiple biophysical techniques (SPR, ELISA etc.)